Clin Res Hepatol Gastroenterol

Clinics and research in hepatology and gastroenterology · ISSN 2210-741X

8 Publications in this journal

Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.

Tran A et al. · Clin Res Hepatol Gastroenterol · 2022

FibroTest HCV
Non-invasive diagnosis and follow-up of portal hypertension.

Thabut D et al. · Clin Res Hepatol Gastroenterol · 2022

FibroTest Alcohol HBV HCV +1
Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.

Peta V et al. · Clin Res Hepatol Gastroenterol · 2020
Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis.

Zarski JP et al. · Clin Res Hepatol Gastroenterol · 2020

ActiTest FibroTest HCV
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014

FibroTest Alcohol HBV HCV +1
Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

Poynard T et al. · Clin Res Hepatol Gastroenterol · 2012

Elasto-FibroTest FibroTest HCV
FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011

FibroTest HCV
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.

Costa JM et al. · Clin Res Hepatol Gastroenterol · 2011

ActiTest FibroTest HCV-GenoFibroTest SteatoTest +1

Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.

Non-invasive diagnosis and follow-up of portal hypertension.

Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.

Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis.

Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.